Does Early Postsurgical Temozolomide Plus Concomitant Radiochemotherapy Regimen Have Any Benefit in Newly-diagnosed Glioblastoma Patients? A Multi-center, Randomized, Parallel, Open-label, Phase II Clinical Trial

BACKGROUND: The radiochemotherapy regimen concomitantly employing temozolomide (TMZ) chemotherapy and radiotherapy (RT) 4 weeks after surgery, followed by 6 cycles of TMZ is a common treatment for glioblastoma (GBM). However, its median overall survival (OS) is only 14.6 months. This study was to ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Ying, Yao, Yu, Zhang, Li-Wei, Lu, Yi-Cheng, Chen, Zhong-Ping, Zhang, Jian-Min, Qi, Song-Tao, You, Chao, Wang, Ren-Zhi, Yang, Shu-Yuan, Zhang, Xiang, Wang, Ji-Sheng, Chen, Ju-Xiang, Yang, Qun-Ying, Shen, Hong, Li, Zhi-Yong, Wang, Xiang, Ma, Wen-Bin, Yang, Xue-Jun, Zhen, Hai-Ning, Zhou, Liang-Fu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736883/
https://www.ncbi.nlm.nih.gov/pubmed/26481741
http://dx.doi.org/10.4103/0366-6999.167313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736883/
https://www.ncbi.nlm.nih.gov/pubmed/26481741
http://dx.doi.org/10.4103/0366-6999.167313

Ejemplares similares